<DOC>
	<DOCNO>NCT00267826</DOCNO>
	<brief_summary>Protocol Title : Immunopharmacological effect Rituximab atopic dermatitis Study Phase : Investigator driven study Study Design : Open-label , single center . Primary Study Objective : To determine efficacy , safety immunopharmacological effect Rituximab ( anti-CD20 ) administer 1000mg intravenous infusion day 1 15 patient atopic dermatitis . Secondary Study Objective : To investigate key immunological parameter involve pathology common skin disease interpret clinical finding . Number Patients : 6 Study Population : Male female patient , least 18 year age atopic dermatitis , active inflammation , severity score 6-9 accord Langeland Rajika . Treatment Group : Rituximab administer 1000 mg infusion intravenously day 1 15 , follow 24-week follow-up period . Visit Schedule : Screening Visit ( within 28 day prior Visit 1 ) Treatment visit ( Visits day 1 , 3 , 8 , 15 , 17 ) Follow-up Visits ( Visits week 4 , 8 , 12 , 16 , 20 , 24 ) Visit 11/Early Termination Visit ( applicable ) Visit 11 serve Early Termination Visit patient withdraws study Visit 1 10 . Efficacy Parameters : Clinical parameter : EASI Patient Assessment Pruritus / Pruritus score Physician Global Assessment ( PGA ) Photography Laboratory analysis : Differential blood count Total IgE , specific IgE ( aeroallergen panel ) Immunophenotyping PBMC Lymphocyte proliferation follow pan-T stimulation PHA Cytokine release blood T cell follow pan-T stimulation PHA Skin test Histopathology skin biopsy Safety Parameters : Physical examination ; vital sign ; select blood chemistry , include liver function test , creatinine ; white blood cell count ( WBC ; include total lymphocyte count ) ; platelet , lymphocyte subset analysis ; complement , immunoglobulin ( IgA , IgM , IgG , IgE ) , monitor infection ; monitor concomitant therapy ; monitor adverse event .</brief_summary>
	<brief_title>Immunopharmacological Effects Rituximab Atopic Dermatitis</brief_title>
	<detailed_description>Investigator driven study Immunopharmacological Effects Rituximab Atopic Dermatitis Investigators 1 . Prof. Dr. Hans-Uwe Simon ( Dept . Pharmacology , University Bern , Switzerland ) 2 . Dr. Dagmar Simon , Prof. Dr. Lasse R. Braathen ( Dept . Dermatology , University Bern , Switzerland ) SUMMARY Protocol Title : Immunopharmacological effect Rituximab atopic dermatitis Study Phase : Investigator driven study Study Design : Open-label , single center . Primary Study Objective : To determine efficacy , safety immunopharmacological effect Rituximab ( anti-CD20 ) administer 1000mg intravenous infusion day 1 15 patient atopic dermatitis . Secondary Study Objective : To investigate key immunological parameter involve pathology common skin disease interpret clinical finding . Number Patients : 6 Study Population : Male female patient , least 18 year age atopic dermatitis , active inflammation , severity score 6-9 accord Langeland Rajika . Treatment Group : Rituximab administer 1000 mg infusion intravenously day 1 15 , follow 24-week follow-up period . Visit Schedule : Screening Visit ( within 28 day prior Visit 1 ) Treatment visit ( Visits day 1 , 3 , 8 , 15 , 17 ) Follow-up Visits ( Visits week 4 , 8 , 12 , 16 , 20 , 24 ) Visit 11/Early Termination Visit ( applicable ) Visit 11 serve Early Termination Visit patient withdraws study Visit 1 10 . Efficacy Parameters : Clinical parameter : EASI Patient Assessment Pruritus / Pruritus score Physician Global Assessment ( PGA ) Photography Laboratory analysis : Differential blood count Total IgE , specific IgE ( aeroallergen panel ) Immunophenotyping PBMC Lymphocyte proliferation follow pan-T stimulation Cytokine release blood T cell follow pan-T stimulation Skin test Histopathology skin biopsy Immunohistochemistry Safety Parameters : Physical examination ; vital sign ; select blood chemistry , include liver function test , creatinine ; white blood cell count ( WBC ; include total lymphocyte count ) ; platelet , lymphocyte subset analysis ; complement , immunoglobulin ( IgA , IgM , IgG , IgE ) , monitor infection ; monitor concomitant therapy ; monitor adverse event . Time schedule : All six patient recruit within 1 year follow approval study Cantonal Ethics Commission ( Bern ) Swissmedic . Aim study In study want investigate clinical efficacy safety well immunopharmacological effect particular inflammatory cell cytokine production AD skin blood treatment rituximab . Primary Objective To determine efficacy safety Rituximab administer 1000 mg intravenous infusion patient atopic dermatitis . Additional Objectives The additional objective study : To investigate influence Rituximab treatment key immunological parameter involve immunopathology AD . STUDY DESIGN Study Outline This open-label , single center study evaluate efficacy safety Rituximab administer 1000 mg intravenous infusion patient atopic dermatitis . 6 patient enrolled . During treatment course , patient receive Rituximab administer 1000 mg intravenous infusion day 1 15 , follow 22-week follow-up period . STUDY POPULATION Number Patients Approximately 6 patient enrol . Study Entry Inclusion Criteria To eligible entry study , candidate must meet following eligibility criterion time enrollment : 1 . Must give write informed consent . 2 . Must least 18 year age 3 . Must diagnose atopic dermatitis fulfil diagnostic criterion Hanfin Rajka active inflammation . 4 . Must severity score 6-9 accord Langeland Rajka . 5 . Must PGA `` moderate '' , `` severe '' `` severe '' pruritus score `` moderate '' `` severe '' baseline . Study Entry Exclusion Criteria Candidates exclude study entry follow exclusion criterion exist time enrollment : 1 . Patients skin disease , might interfere evaluation AD 2 . Patients severe disease organ system ( e.g . cardiovascular , liver , kidney , psychiatric , neurologic ) might put patient risk study might interfere evaluation ( opinion investigator ) 3 . Patient old 65 year 4 . Systemic treatment atopic dermatitis ( e. g. corticosteroid , cyclosporine , mycophenolat- mofetil , interferon-gamma , UVB , UVA , PUVA ) systemic treatment immunosuppressive/immunomodulating substance ( e.g . azathioprin , methotrexate , biologics hyposensitization -therapy ) within 28 day prior baseline . 5 . Local treatment atopic dermatitis pimecrolimus/tacrolimus , steroid &gt; class III , instable use steroid class &lt; III , emollients local antiseptics/antibiotics within 14 day prior day 1 . 6 . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose Rituximab . 7 . History recurrent clinically significant infection . 8 . Congenital acquire immunodeficiency syndrome . 9 . History new diagnosis treatment invasive malignancy within 5 year enrollment . Patients history treat squamous cell and/or basal cell carcinoma limit skin exclude . 10 . For female patient , unless postmenopausal surgically sterile , unwillingness practice effective contraception , define investigator , study . The rhythm method use sole method contraception . Female patient consider become pregnant study exclude . 11 . Female patient currently pregnant breast-feeding . 12 . Current enrollment investigational drug study . 13 . Previous participation study previous study Rituximab . Screening Log Participating investigational site require document screen candidate initially consider inclusion study specifically state reason ( ) exclusion . STUDY MEDICATION , DESCRIPTION , AND ALLOCATION Investigational Drug Rituximab supply Roche Pharma ( Schweiz ) AG . Rituximab register treatment B cell lymphoma Switzerland . Investigational site personnel refer Directions Handling Administration ( DHA ) specific instruction handle administration Rituximab . Enrollment Procedure Patients officially enrol study assign subject identification number screen evaluation complete study inclusion criterion meet . Drug Accountability Rituximab accountability must maintain investigator . The investigator must maintain accurate record demonstrate date amount Rituximab receive , dispense ( patient-by-patient accounting ) , account Rituximab accidentally deliberately destroy . Unless otherwise notify , vial , use unused save . THERAPY Once therapy ( , dose number 1 ) begin , order patient receive subsequent dose Rituximab , follow must occur : - administration dose Rituximab must separate interval least 7 day - clinical evidence significant viral , bacterial , fungal infection time study visit Treatment Schedule During treatment course , patient receive Rituximab administer 1000 mg intravenous infusion , follow 24-week follow-up period . Dosing accord schedule provide unless evidence clinically significant infection ( determined investigator ) leukopenia , neutropenia thrombocytopenia . Treatment Compliance Compliance Rituximab dosing monitor record investigational site personnel . Concomitant Therapy For patient prescription medication , every attempt make keep patient stable dose medication least 14 day prior first dose Rituximab treatment course . Any medication non-drug procedure therapy ( include topical emollient ) use study entry patient 's final study visit must record patient 's CRF . Allowed Concomitant Therapy Patients two intravenous infusion Rituximab either monotherapy combination follow class treatment describe . Treatments keep stable period 14 day baseline Visit 13 . - Topical low medium potency corticosteroid - Topical emollient - Topical antiseptic antibiotic - Oral Antihistamines Disallowed Concomitant Therapy At time study participation may patient receive treatment : • live vaccine live attenuate vaccine • therapy active tuberculosis tuberculosis prophylaxis - UVB , UVA , UVA1 - Psoralen plus ultraviolet A ( PUVA ) - cyclosporine , methotrexate , prednisone , azathioprine , thioguanine systemic immunosuppressant agent - topical pimecrolimus tacrolimus - high potency topical corticosteroid - another investigational drug approve therapy investigational use . - kind allergenspecific immunotherapy EFFICACY ASSESSMENTS Clinical Efficacy Assessments All efficacy assessment perform investigator patient . • PGA • EASI • Patient´s Pruritus Assessment • Photography Laboratory/Histologic Efficacy Assessments Laboratory analysis : Differential blood count , platelet Total IgE , specific IgE ( aeroallergen panel ) Immunophenotyping PBMC ( Lymphocyte proliferation follow pan-T stimulation ) Cytokine release blood T cell follow pan-T stimulation Skin test Histopathology skin biopsy Immunohistochemistry SAFETY ASSESSMENTS Clinical Safety Assessments - Physical examination ( include vital sign , sign infection ) - Monitoring new ongoing infection - Monitoring concomitant therapy - Monitoring adverse event Laboratory Safety Assessments - Selected blood chemistry - pregnancy test . Product/Trial-Specific Assessments - WBC ( Including total lymphocyte count ) - Platelets Adverse Events : Definition Management The term `` relationship '' `` severity '' ( use throughout section ) define table . At time write informed consent , patient must give name phone number investigational site personnel call event emergency report medical symptom untoward medical occurrence concern patient . Definitions Predosing Signs Symptoms For purpose study , sign ( include abnormal laboratory result , determine investigator ) medical diagnosis note medical personnel , symptom report patient occurs prior start investigational drug treatment consider predosing sign/symptom . Any predosing sign/symptom classify serious report IRB/REB/IEC . Adverse Events For purpose study , sign ( include abnormal laboratory result , determine investigator ) medical diagnosis note medical personnel , symptom report patient , regardless relationship investigational drug , treatment-emergent consider adverse event . 'Treatment-emergent ' define follow : 1 . Has onset time start investigational drug treatment OR 2 . Has worsen since event previously report ( include worsening sign , symptom , diagnose present prior first dose investigational drug worsen time start investigational drug treatment ) Classification Event Serious As soon patient give write informed consent participate study , abnormal sign ( include abnormal laboratory result , determine investigator ) medical diagnosis note medical personnel , symptom report patient regardless whether patient receive investigational drug classify investigator either serious non-serious event use follow definition : Serious Event Events classify serious meet follow criterion ( accordance 21 CFR Part 312.32 recommendation International Conference Harmonization [ Federal Register , October 7 , 1997 , Vol . 62 , No . 194 , pp 52239-45 ] ) : • Any death . • Any life-threatening event , i.e. , event place patient , view investigator , immediate risk death event occur ( include event , occur severe form , might cause death ) . • Any event require prolongs in-patient hospitalization . • Any event result persistent significant disability/incapacity . - Any congenital anomaly/birth defect diagnose child patient participate study . - Other medically important event opinion investigator may jeopardize patient may require intervention prevent one outcomes listed definition . Immediate Telephone Reporting Serious Events Roche Pharma ( Schweiz ) AG must immediately make aware event classify SERIOUS order adhere applicable law regulation report serious event . Therefore , investigator 's responsibility ensure follow : Any serious event occur time patient sign inform consent form study , regardless whether patient undergone study-related procedure receive investigational drug , patient 's final study visit ( i.e. , Visit 11 ) , inclusive , must report Roche Pharma ( Schweiz ) AG within 24 hour follow report event , regardless severity relationship investigational drug . When telephone serious event report Roche Pharma ( Schweiz ) AG , investigator must provide specific information regard patient event . Roche Pharma ( Schweiz ) AG must also receive write confirmation information . For death occur follow patient 's enrollment study Record Death CRF well copy autopsy report ( when/if available ) must submit Roche Pharma ( Schweiz ) AG . The investigator must keep copy documentation relate event site 's study file . The investigator must also notify local review committee , i.e. , Institutional Review Board ( IRB ) , Research Ethics Board ( REB ) , per local IRB/REB/IEC requirement . Documentation report keep site 's study file . Any serious event onset patient 's first dose investigational drug unresolved time patient permanently discontinue study must follow event resolve patient 's clinical course stabilize . Reporting Serious Events Regulatory Agencies After receipt serious event report Roche Pharma ( Schweiz ) AG notify appropriate regulatory authority , necessary , within require time frame . Written safety report submit regulatory authority complete Roche Pharma ( Schweiz ) AG assistance investigator investigational site personnel , need . Primary Endpoints Primary endpoint change EASI Visit 7 24 compare baseline via paired t-Test . Additional Endpoints Additional endpoint percentage patient reach PGA `` clear '' `` almost clear '' and/or reduction EASI &gt; = 50 &gt; = 75 % compare baseline visit baseline . Other additional endpoint : percentage patient reach pruritus score `` none '' `` mild '' Several immunological endpoint Criteria Endpoints Patients miss PGA score visit analyze consider treatment failure visit . Patients receive disallowed therapy list prior visit course analyze consider treatment failure course efficacy analysis . Statistical Methods Analysis Populations 1.1.1.1 Safety The safety population define patient receive least 1 dose study drug least 1 post-baseline assessment safety parameter . 1.1.1.2 Efficacy The efficacy population base intent-to-treat principle define patient receive least 1 dose study drug . Demographics statistical aspect All appropriate background data summarize presenting frequency distribution and/or basic summary statistic ( mean , standard deviation , median , minimum , maximum ) . Study question hypothesis Due pilot character study formal hypothesis issue . We expect clear improvement Rituximab . The effect Rituximab special interest , may become new therapeutic approach reasonable cost handle . Our investigation pilot trial follow study enrol large population elucidate clinical use treatment patient atopic dermatitis . Statistical method Changes investigate variable treatment compare use Wilcoxon 's signed rank test . Subgroups compare use Mann Whitney U-test . Otherwise , data analyse presented desriptive manner ( see ) . Safety Analyses All clinical adverse event laboratory abnormality evaluate safety . The number patient least 1 dose withheld also evaluate . 1.1.1.3 White blood cell count , platelet Lymphocyte lymphocyte subset ( CD4+ CD8+ ) count time present . 1.1.1.4 Laboratory Abnormalities Selected blood chemistry evaluation assess determine incidence laboratory abnormality emerge within course . Shift table use present change laboratory parameter relative parameter 's normal range . 1.1.1.5 Physical Examinations Vital Signs The incidence abnormalities physical examination vital sign , respectively , present . Efficacy Analyses The proportion patient achieve PGA `` almost clear '' `` clear '' decrease EASI value &gt; =50 % &gt; =75 % without use disallow therapy define protocol schedule visit present . The EASI Visit 3-11 compare EASI baseline/Day1 use pair t-test . The threshold significant change p &lt; 0,05 . APPENDIX 1 : ECZEMA AREA AND SEVERITY INDEX ( EASI ) The EASI assigns proportionate body surface area head neck [ 10 % ] , trunk [ 30 % ] , upper extremity [ 20 % ] low extremity [ 40 % ] child age 7 . This roughly consistent rule nine . The number modify used child age 7 : head neck [ 20 % ] , trunk [ 30 % ] , upper extremity [ 20 % ] low extremity [ 30 % ] . The area involvement ( affected inflammation , include dry skin ) four body region represent numeric cod value [ 0 - 6 ] ( investigator require record percent area CRF ) . Table 1 . EASI : Area involvement Area Involvement 0 1 2 3 4 5 6 eruption &lt; 10 % 10 % - 29 % 30 % - 49 % 50 % - 69 % 70 % - 89 % 90 % - 100 % The head , trunk , upper limb low limb assess separately erythema ( E ) , infiltration/papulation ( I ) , excoriation ( Ex ) lichenification ( L ) . The average degree severity sign four body part , assign score 0-3 indicate none ( 0 ) , mild ( 1 ) , moderate ( 2 ) severe ( 3 ) expression clinical sign . Half step allow . Further practical detail aid assessment : The low extremity region include buttock . The trunk region include internal/medial axilla groin . The head/neck region comprise face anterior posterior neck . The upper extremity region include hand external axilla . The definition score sign EASI give : Table 2 . Scoring sign EASI Erythema ( E ) 0 None 1 Mild Faintly detectable erythema : light pink 2 Moderate Dull red , clearly distinguishable 3 Severe Deep / dark red Infiltration / Papulation ( I ) 0 None 1 . Mild Barely perceptible elevation 2 . Moderate Clearly perceptible elevation extensive 3 . Severe Marked extensive elevation Excoriations ( Ex ) 0 None 1 Mild Scant evidence excoriation sign deeper skin damage ( erosion , crust ) 2 Moderate Several linear mark skin show evidence deeper skin injury ( erosion , crust ) 3 Severe Many erosive crusty lesion Lichenification ( L ) 0 None 1 . Mild Slight thicken skin discernible touch skin marking minimally exaggerate 2 . Moderate Definite thicken skin skin marking exaggerate form visible criss-cross pattern 3 . Severe Thickened indurated skin skin marking visibly portray exaggerated criss-cross pattern The EASI calculate accord follow formula : Table 3 . EASI : Calculation score age 7 year Head/Neck ( E + I + Ex + L ) x Area ( 1 ) x 0.1 Trunk ( E + I + Ex + L ) x Area ( 1 ) x 0.3 Upper limb ( E + I + Ex + L ) x Area ( 1 ) x 0.2 Lower limb ( E + I + Ex + L ) x Area ( 1 ) x 0.4 EASI = sum four body area 1 . Where Area define Seven Point Ordinal Scale , show table 3-3 . Dermatologists Signature : _______________________________ date ( dd/MMM/yyyy ) : ____/____/_____ APPENDIX 2 : PHYSICIAN GLOBAL ASSESSMENT OF EFFICACY Please mark box base patient 's condition time visit . Clear Almost Clear Mild Moderate Severe Very Severe 1 0 2 0 3 0 4 0 50 6 0 Very Severe = severe erythema severe papulation infiltration oozing/crusting Severe = severe erythema severe papulation infiltration Moderate = moderate erythema moderate papulation infiltration Mild = mild erythema mild papulation infiltration Almost Clear = perceptible erythema perceptible papulation infiltration Clear = No inflammatory sign AD APPENDIX 3 : PRURITUS SEVERITY SCORE IN AVERAGE ABOUT THE LAST WEEK Severe Moderate Mild Absent 1 . 0 2 0 3 0 4 0 Severe = Intense itch severe sleep disturbance Moderate = Moderate itch sleep disturbance Mild = mild itch without sleep disturbance Absent = itch</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Must give write informed consent . Must least 18 year age . Must diagnose atopic dermatitis fulfil diagnostic criterion Hanfin Rajka active inflammation . Must severity score 69 accord Langeland Rajka . Must PGA `` severe '' `` severe '' pruritus score `` moderate '' `` severe '' baseline . Patients skin disease might interfere evaluation AD . Patients severe disease organ system ( e.g . cardiovascular , liver , kidney , psychiatric , neurologic ) might put patient risk study might interfere evaluation ( opinion investigator ) . Patient old 65 year . Systemic treatment atopic dermatitis ( e. g. corticosteroid , cyclosporine , mycophenolatmofetil , interferongamma , UVB , UVA , PUVA ) systemic treatment immunosuppressive/immunomodulating substance ( e.g . azathioprin , methotrexate , biologics hyposensitization therapy ) within 28 day prior baseline . Local treatment atopic dermatitis pimecrolimus/tacrolimus , steroid &gt; class III , instable use steroid class &lt; III , emollients local antiseptics/antibiotics within 14 day prior day 1 . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose Rituximab . History recurrent clinically significant infection . Congenital acquire immunodeficiency syndrome . History new diagnosis treatment invasive malignancy within 5 year enrollment . Patients history treat squamous cell and/or basal cell carcinoma limit skin exclude . For female patient , unless postmenopausal surgically sterile , unwillingness practice effective contraception , define investigator , study . The rhythm method use sole method contraception . Female patient consider become pregnant study exclude . Female patient currently pregnant breastfeeding . Current enrollment investigational drug study . Previous participation study previous study Rituximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Anti-CD20 antibody treatment</keyword>
	<keyword>Atopic dermatitis</keyword>
	<keyword>B cell</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Immunopathology</keyword>
</DOC>